Physician profile
Scott E Auty
NPI 1801980917
$4,656.45
in general payments reported to CMS, 2019-2025
34 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,924 · 2022: $1,754 · 2023: $625 · 2024: $89.53 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.20 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $678.63 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $553.02 | 2021-2025 | |
| Glaxosmithkline, LLC. | $372.06 | 2021-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $369.18 | 2021-2024 | Mounjaro, Trulicity, Zepbound |
| Amgen INC. | $357.95 | 2021-2023 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $337.35 | 2021-2023 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $267.06 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $196.95 | 2021-2023 | Seglentis |
| Exact Sciences Corporation | $193.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.08 | 2021-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $137.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $88.22 | 2022 | |
| Pfizer INC. | $86.68 | 2021-2023 | |
| Almatica Pharma LLC | $81.09 | 2021-2023 | Sertraline Hcl, Loreev Xr |
| Mannkind Corporation | $73.07 | 2023 | Afrezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $72.45 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Teva Pharmaceuticals USA, INC. | $53.71 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $53.41 | 2022 | |
| Bausch Health US, LLC | $45.07 | 2021-2023 | Aplenzin, Wellbutrin |
| Ethicon US, LLC | $44.42 | 2025 | Stratafix |
| Biohaven Pharmaceuticals, INC. | $44.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $42.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.59 | 2021 | |
| Idorsia Pharmaceuticals US INC | $39.82 | 2022-2023 | Quviviq |
| Abbott Laboratories | $38.66 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $38.11 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $30.33 | 2021-2022 | |
| Adlon Therapeutics L.P. | $28.54 | 2021 | |
| Genentech USA, INC. | $27.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.80 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.44 | 2021 | |
| Kaleo, INC. | $14.20 | 2022 | |
| Medtronic, INC. | $12.93 | 2023 | Closurefast |
| E.R. Squibb & Sons, L.L.C. | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Auty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.